BioCorRx Inc. – OTC:BICX

Add to watchlist

$0.242

-0.13

-36.24%

Market closed

Open in 1 day

-30.91%

month

-30.91%

quarter

-54.76%

year

Market Cap	14.64M
Enterprise value	14.35M

P/E	-2.9
EV/Sales	57.31
EV/EBITDA	-2.94
Price/Sales	50.89
Price/Book	-1.55
PEG ratio	-0.11
EPS	-0.45

Revenue	52.33K
EBITDA	-2.95M
Income	-3.99M
Revenue Q/Q	-91.04%
Revenue Y/Y	-77.61%

Profit margin	-2648.14%
Oper. margin	-2868.27%
Gross margin	42.09%
EBIT margin	-2868.27%
EBITDA margin	-5645.77%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

BioCorRx Inc. (OTC:BICX): Profit margin
Jun 2023	19.63K	-922.44K	-4697.94%
Sep 2023	10.14K	-866.28K	-8538.98%
Dec 2023	18.93K	-968.54K	-5114.27%
Mar 2024	3.62K	-1.23M	-34165.08%

BioCorRx Inc. (OTC:BICX): Debt to assets
Jun 2023	756759	9.46M	1251.03%
Sep 2023	534446	9.79M	1832.71%
Dec 2023	388887	10.34M	2659.23%
Mar 2024	317444	11.18M	3523.64%

BioCorRx Inc. (OTC:BICX): Cash Flow
Jun 2023	-571.54K	565.16K
Sep 2023	-350.54K	309.65K
Dec 2023	-533.83K	442.64K
Mar 2024	-339.66K	375.52K

BioCorRx alternative data

BioCorRx Inc. (OTC:BICX): Employee count
Mar 2024	3
Apr 2024	3
May 2024	3
Jun 2024	3
Jul 2024	3

BioCorRx Inc. (OTC:BICX): Insider trades (number of shares)
Period	Buy	Sel
Apr 2023	171296	0
Jan 2024	3126	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	16 Jan 2024	LUCIDO LOUIS C. director, 10 percent owner, officer: Inter.. director, 10 percent owner, off..	Common Stock, par value $0.001	126	$0.7	$88
Purchase	12 Jan 2024	LUCIDO LOUIS C. director, 10 percent owner, officer: Inter.. director, 10 percent owner, off..	Common Stock, par value $0.001	3,000	$0.7	$2,100
Purchase	3 Apr 2023	LUCIDO LOUIS C. director, 10 percent owner: director, 10 percent owner:	Common Stock, par value $0.001	171,296	$1.75	$299,768
Purchase	30 Jan 2023	LUCIDO LOUIS C. director, 10 percent owner director, 10 percent owner	Common Stock, par value $0.001	100	$1.37	$137
Purchase	30 Jan 2023	LUCIDO LOUIS C. director, 10 percent owner director, 10 percent owner	Common Stock, par value $0.001	300	$1.39	$417
Purchase	26 Jan 2023	LUCIDO LOUIS C. director, 10 percent owner director, 10 percent owner	Common Stock, par value $0.001	500	$1.29	$647
Purchase	24 Jan 2023	LUCIDO LOUIS C. director, 10 percent owner director, 10 percent owner	Common Stock, par value $0.001	200	$1.2	$240
Purchase	13 Jan 2023	LUCIDO LOUIS C. director, 10 percent owner director, 10 percent owner	Common Stock, par value $0.001	2,000	$1.15	$2,300
Purchase	13 Jan 2023	LUCIDO LOUIS C. director, 10 percent owner director, 10 percent owner	Common Stock, par value $0.001	2,000	$1.1	$2,200
Purchase	3 Jan 2023	LUCIDO LOUIS C. director, 10 percent owner director, 10 percent owner	Common Stock, par value $0.001	2,000	$1.1	$2,200

BioCorRx
Executives

Insider	Age	Compensation
Mr. Brady James Granier (1972) Pres & Director	53	$271,220
Ms. Lourdes Felix (1968) Chief Executive Officer, Chief Financial Officer & Director	57	$250,000
Mr. Thomas Patrick Welch (1972) Executive Vice President	53	$162,730

BioCorRx
Latest News

Thursday, 15 August 2024
08:30	BioCorRx Reports Business Update for the Second Quarter of 2024	globenewswire.com
Wednesday, 3 April 2024
08:30	BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia	globenewswire.com
Tuesday, 2 April 2024
08:30	BioCorRx Reports Business Update for 2023	globenewswire.com
Wednesday, 28 February 2024
10:49	BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD	globenewswire.com
Thursday, 8 February 2024
09:52	BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors	globenewswire.com
Tuesday, 9 January 2024
08:30	BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President	globenewswire.com
Tuesday, 14 November 2023
12:52	BioCorRx Reports Business Update for the Third Quarter of 2023	globenewswire.com
Friday, 27 January 2023
08:30	BioCorRx to Present at Sequire Biotechnology Conference on February 2nd	GlobeNewsWire
Monday, 24 October 2022
11:30	BioCorRx to Present at the LD Micro Main Event XV on October 25th	Newsfile Corp
Tuesday, 6 September 2022
08:30	BioCorRx to Present at the H.C. Wainwright 24th Annual Global Investment Conference	GlobeNewsWire
Tuesday, 31 May 2022
09:00	BioCorRx to Present at the LD Micro Invitational XII on June 7th	GlobeNewsWire
Tuesday, 22 March 2022
08:30	BioCorRx to Participate in Two Upcoming Conferences	GlobeNewsWire
Wednesday, 2 March 2022
08:30	BioCorRx to Present at the Q1 Investor Summit Conference on March 9th	Newsfile Corp

Frequently Asked Questions (FAQ)

What's the price of BioCorRx stock today?

One share of BioCorRx stock can currently be purchased for approximately $0.24.
When is BioCorRx's next earnings date?

Unfortunately, BioCorRx's (BICX) next earnings date is currently unknown.
Does BioCorRx pay dividends?

No, BioCorRx does not pay dividends.
How much money does BioCorRx make?

BioCorRx has a market capitalization of 14.64M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 58.31% to 89.16K US dollars.
What is BioCorRx's stock symbol?

BioCorRx Inc. is traded on the OTC under the ticker symbol "BICX".
What is BioCorRx's primary industry?

Company operates in the Healthcare sector and Medical Care Facilities industry.
How do i buy shares of BioCorRx?

Shares of BioCorRx can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are BioCorRx's key executives?
BioCorRx's management team includes the following people:
- Mr. Brady James Granier Pres & Director(age: 53, pay: $271,220)
- Ms. Lourdes Felix Chief Executive Officer, Chief Financial Officer & Director(age: 57, pay: $250,000)
- Mr. Thomas Patrick Welch Executive Vice President(age: 53, pay: $162,730)
When BioCorRx went public?

BioCorRx Inc. is publicly traded company for more then 15 years since IPO on 1 Sep 2010.
What is BioCorRx's official website?

The official website for BioCorRx is biocorrx.com.
Where are BioCorRx's headquarters?

BioCorRx is headquartered at 2390 East Orangewood Avenue, Anaheim, CA.
How can i contact BioCorRx?

BioCorRx's mailing address is 2390 East Orangewood Avenue, Anaheim, CA and company can be reached via phone at +7 144624880.

BioCorRx Inc.

biocorrx.com

Exchange:

OTC

Full time employees:

Industry:

Medical Care Facilities

Sector:

Healthcare

BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.

+7 144624880

2390 East Orangewood Avenue
Anaheim, CA 92806

CIK: 0001443863
ISIN: US09073C2052
CUSIP: 09073C205